Saporins

Type 1 ribosome-inactivating proteins derived from SAPONARIA OFFICINALIS that function through endohydrolysis of the N-glycosidic bond at single ADENOSINE residues of 28S RIBOSOMAL RNA. They are used as IMMUNOTOXINS.

Also Known As:

Ribosome-Inactivating Protein; SAP5 Protein; SAP6 Protein; Saporin; Saporin 5 Protein; Saporin 6 Protein; Saporin Protein; Saporin-S9 Protein; Protein, RIP Ribosome-Inactivating; RIP Ribosome Inactivating Protein; Ribosome Inactivating Protein; Ribosome-Inactivating Protein, RIP; Saporin S9 Protein; RIP Ribosome-Inactivating Protein

Networked: 330 relevant articles (24 outcomes, 34 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Flavell, David J: 7 articles (03/2021 - 02/2015)
2.	Bolognesi, Andrea: 7 articles (01/2017 - 01/2002)
3.	Polito, Letizia: 7 articles (01/2017 - 01/2002)
4.	Flavell, Sopsamorn U: 6 articles (03/2021 - 02/2015)
5.	Nichols, Nicole L: 5 articles (01/2022 - 10/2018)
6.	Holmes, Suzanne E: 5 articles (03/2021 - 02/2015)
7.	Angelucci, Francesco: 5 articles (01/2021 - 07/2015)
8.	Fabbrini, Maria Serena: 5 articles (01/2021 - 01/2009)
9.	Giansanti, Francesco: 5 articles (01/2021 - 07/2015)
10.	Ippoliti, Rodolfo: 5 articles (01/2021 - 07/2015)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2020 - "Notably, saporin-loaded GE11-CPs revealed low toxicity, effective tumor inhibition and significant improvement of survival rate compared with PBS and non-targeted groups (median survival time: 99 versus 37 and 42 days). " 07/21/2022 - "Saporin Toxin Delivered by Engineered Colloidal Nanoparticles Is Strongly Effective against Cancer Cells." 04/01/2019 - "In vitro and in vivo studies demonstrated promising results in terms of tumor growth inhibition after the delivery of a suicide gene such as saporin and dianthin. " 02/21/2020 - "Our findings suggest that the EC16-1/saporin combination could potentially be a novel therapeutic treatment in patients with parental or ABCB1- and ABCG2-positive drug-resistant cancers." 09/01/2010 - "Studies with intravenous application of a recombinant type II ribosome inactivating protein (rML) analogous to nML revealed a short half-life of about 13 min in cancer patients. "
2.	Hypersensitivity (Allergy) 02/01/2016 - "DβH-saporin treatment resulted in a significant prolongation in the duration of mechanical and to a lesser degree thermal hypersensitivity in the ipsilateral paw of incised rats but did not increase the duration of spontaneous guarding. " 09/01/2010 - "Findings from the two CRF-Saporin studies determined that pre-treatment with this toxin significantly attenuated SNL- and carrageenan-induced tactile hypersensitivity. " 08/29/2011 - "Dermorphin-saporin, but not saporin, microinjections prevented the development of hind paw mechanical hypersensitivity, but did not affect the defensive-aggressive behaviors. " 05/01/2019 - "Ablation of the superficial NK1Rs with an intrathecal injection of a substance P analog conjugated to the toxin saporin (SSP-SAP) eliminated the thermal hypersensitivity of dab1-/- mice, without altering their mechanical insensitivity. " 01/01/2016 - "Selective ablation of mu-opioid receptor (MOR)-expressing neurons in the RVM using saporin conjugated to the MOR agonist dermorphin-saporin (derm-sap) attenuates stress and injury-induced behavioral hypersensitivity, yet the effect of RVM derm-sap on the functional integrity of the descending inhibitory system and the properties of RVM neurons remain unknown. "
3.	Hodgkin Disease (Hodgkin's Disease) 03/01/1996 - "The anti-CD30 immunotoxin (IT) Ber-H2/saporin is effective in patients with refractory Hodgkin's disease. " 05/01/2009 - "The purpose of this work was to compare the pathways of cell death induced by the RIP saporin with those carried out by ricin in the L540 human Hodgkin's lymphoma-derived cell line. " 09/01/1998 - "Targeting of saporin to Hodgkin's lymphoma cells by anti-CD30 and anti-CD25 bispecific antibodies." 10/01/1995 - "Among CD25-CD30+ Hodgkin's lymphoma lines, which were resistant to targeting by anti-CD25/saporin BsmAb, one (L428) was sensitive to both gelonin and saporin delivered by anti-CD30 BsmAb. " 10/01/1995 - "In this study, we compared the ability of different bispecific monoclonal antibodies (BsmAb) and immunotoxins to deliver the type 1 ribosome-inactivating proteins (RIP) saporin and gelonin through the CD25 or CD30 target molecules to Hodgkin's lymphoma cells. "
4.	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 08/01/1991 - "These studies have clearly demonstrated the effectiveness of this BsAb for delivering saporin to a T-ALL cell line utilising CD7 as the target molecule on the cell surface. " 08/01/1994 - "A SCID mouse model of human T-ALL has been used to determine the in vivo therapeutic efficacy of two anti-CD7-saporin immunotoxins constructed with either a hindered (HB2-SMPT-Sap) or non-hindered (HB2-SPDP-Sap) disulphide bond between antibody and saporin. " 12/15/1998 - "We have investigated the anti-leukemia effect that is exerted by the murine anti-CD7 antibody HB2 in a severe combined immunodeficient (SCID) mouse model of human T-cell acute lymphoblastic leukemia (T-ALL) and determined the contribution that this antibody effect makes to the therapeutic potency of a saporin immunotoxin (IT) constructed with the same antibody. " 04/01/1992 - "We have investigated the effectiveness of three different F(ab' gamma)2 bispecific antibodies (BsAb) for delivering the ribosome inactivating protein (RIP) saporin via the CD7 or CD38 cell surface molecules to the human T-ALL cell lines HSB-2 and HPB-ALL. "
5.	Lymphoma (Lymphomas) 07/01/2005 - "An anti-CD38 mAb (IB4) coupled to saporin-S6, a type 1 ribosome-inactivating protein (RIP), was designed for ex vivo or loco-regional therapeutical applications in myeloma and lymphoma. " 01/01/1992 - "Initial experience in treating human lymphoma with a combination of bispecific antibody and saporin." 11/15/1988 - "Bispecific F(ab' gamma)2 antibody for the delivery of saporin in the treatment of lymphoma." 09/01/2006 - "Conjugation of the sialoside probes to the toxin saporin resulted in toxin uptake and toxin-mediated killing of B lymphoma cell lines, suggesting an alternative approach for targeting CD22 for treatment of B cell lymphomas." 01/01/2019 - "The data support the hypothesis that endocytic processes are involved in the augmentative action of SA for saporin ITs targeted against a range of antigens expressed by leukaemia and lymphoma cells. "

Related Drugs and Biologics

1.	Immunotoxins (Immunotoxin)
2.	Proteins (Proteins, Gene)
3.	Substance P
4.	Monoclonal Antibodies
5.	Gelonium multiflorum GEL protein
6.	Saponins
7.	substance P-saporin
8.	Cytotoxins (Cytolysins)
9.	Momordica charantia MMC protein
10.	Antigens

Related Therapies and Procedures

1.	Therapeutics
2.	Spinal Injections
3.	General Anesthesia
4.	Injections
5.	Ligation